Skip to content
Excalibur – Randomized Controlled Trial Logo Excalibur – Randomized Controlled Trial Logo Excalibur – Randomized Controlled Trial Logo
  • The Excalibur Project
  • The Trials
    • EXCALIBUR-1
      • About the Trial
      • Inclusion/exclusion-critera
    • EXCALIBUR-2
      • About the Trial
      • Inclusion/exclusion-critera
  • News
  • Check your patient
  • Study Group
  • FAQ
  • Archive
  • Contact
  • The Excalibur Project
  • The Trials
    • EXCALIBUR-1
      • About the Trial
      • Inclusion/exclusion-critera
    • EXCALIBUR-2
      • About the Trial
      • Inclusion/exclusion-critera
  • News
  • Check your patient
  • Study Group
  • FAQ
  • Archive
  • Contact
  • The Excalibur Project
  • The Trials
    • EXCALIBUR-1
      • About the Trial
      • Inclusion/exclusion-critera
    • EXCALIBUR-2
      • About the Trial
      • Inclusion/exclusion-critera
  • News
  • Check your patient
  • Study Group
  • FAQ
  • Archive
  • Contact

April 2023: SLV/REK approved the 2c-stratum

John Brataas2023-09-05T08:19:57+00:00

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

ClinicalTrails ID

NCT04898504
NCT04840186

Sponsors:

Copyright 2021- Oslo Universitetssykehus HF, Rikshospitalet | All Rights Reserved | Design by WebPress
Page load link
Go to Top